Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | ALPL | P05186 | 12/20 | 0.60 |
| ▸ | CA12 | O43570 | 5/20 | 0.60 |
| ▸ | RPA1 | P27694 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.55 |
| ▸ | HPGDS | O60760 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MARS1 | P56192 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1816813 | 0.81 | TP53 (0.73) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL222852 | 0.79 | TP53 (0.74) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL726574 | 0.78 | TP53 (1.00) | TP53ALPLCA12RPA1CA9 | |
| Hydrochloric Acid SCHEMBL27639048 | 0.77 | TP53 (0.72) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL31412652 | 0.76 | TP53 (0.65) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL2838112 | 0.76 | TP53 (0.73) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL1414100 | 0.75 | ALPL (1.00) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL2658851 | 0.75 | ALPL (0.73) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL2885575 | 0.74 | ALPL (0.66) | TP53ALPLCA12RPA1CA9 | |
| SCHEMBL15094586 | 0.74 | ALPL (1.00) | TP53ALPLCA12RPA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | BANTAM PHARMACEUTICAL LLC (US) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210278408-A1 | METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS | TP53, MKI67, VHL | TP53 1/4885ALPL 4652/4885CA12 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.